Dual Antiplatelet Therapy in Patients With Metabolic Syndrome After Mild Ischemic Stroke or Transient Ischemic Attack.

ABSTRACT:

Background

Metabolic syndrome (MetS) attenuates antiplatelet agent effects. This study investigated the efficacy and safety of clopidogrel-aspirin therapy for secondary stroke prevention in patients with MetS.

Methods

Data were obtained from the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis) trial. Patients with mild ischemic stroke or high-risk transient ischemic attack were randomized to treatment with clopidogrel-aspirin or aspirin alone within 72 hours after symptom onset. MetS was defined according to the Adult Treatment Panel-III. The primary efficacy outcome was new stroke, and the primary safety outcome was moderate - to - severe bleeding within 90-day follow-up. Differences between groups were es

SUBMITTER: Xia Z 

PROVIDER: S-EPMC12449989 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature